Skip to Content
Merck

T7080

Tazarotene

≥98% (HPLC), prodrug of tazarotenic acid, powder

Synonym(s):

6-[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester, AGN-190168, ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C21H21NO2S
CAS Number:
118292-40-3
Molecular Weight:
351.46
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Tazarotene, ≥98% (HPLC)

SMILES string

S1CCC(c2c1ccc(c2)C#Cc3ncc(cc3)C(=O)OCC)(C)C

InChI

1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3

InChI key

OGQICQVSFDPSEI-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to very faintly yellow

solubility

DMSO: >15 mg/mL

originator

Allergan

storage temp.

2-8°C

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene.
Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene. It is a prodrug of tazarotenic acid, which specifically activates RARb and RARg, only weakly activates RARa, and is inactive at retinoid X receptors (RXRs). In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation.

Features and Benefits

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Allergan. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361d

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
106M4755V
085M4707V
021M4717V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Lebwohl
Journal of the American Academy of Dermatology, 43(2 Pt 3), S43-S46 (2000-07-18)
In the treatment of plaque psoriasis with corticosteroids, long-term efficacy and safety are often compromised by tachyphylaxis, steroid rebound, and adverse effects. However, the results of recent studies demonstrate that the use of tazarotene in conjunction with a corticosteroid can
D D Tang-Liu et al.
Clinical pharmacokinetics, 37(4), 273-287 (1999-12-20)
Tazarotene (AGN 190168) is a new acetylenic retinoid which is effective for the topical treatment of patients with stable plaque psoriasis and mild to moderate acne vulgaris. Topical gel application provides direct delivery of tazarotene into the skin. At 10
A Roeder et al.
Skin pharmacology and physiology, 17(3), 111-118 (2004-04-17)
Tazarotene is a member of the new generation of receptor-selective, synthetic retinoids for the topical treatment of mild to moderate plaque psoriasis, acne vulgaris and photoaging. Though they are effective in monotherapy, clinical studies with a focus on novel combination
Mark A Hyde et al.
Archives of dermatology, 148(5), 592-596 (2012-03-21)
To determine if the complete response rates of lentigo maligna (LM) to imiquimod, 5%, cream can be improved by the addition of a topical retinoid. Prospective randomized study of patients treated with imiquimod alone vs imiquimod plus a topical retinoid
Ritu Saini et al.
Current pharmaceutical design, 11(2), 273-280 (2005-01-11)
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of biologic therapies for this disease. The
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service